Lantheus Holdings, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 92/100
What the filing says
On August 3, 2026, Lantheus entered into a definitive merger agreement with Curium US Holdings LLC. Curium will acquire all outstanding Lantheus shares for $102.50 per share in cash plus contingent value rights (CVRs) worth up to $12.00 per share (total consideration up to $114.50/share), representing a total transaction value of approximately $8.0 billion. The deal, unanimously approved by Lantheus's Board, creates a combined radiopharmaceutical company spanning diagnostics and therapeutics serving 70+ countries. Q2 2026 standalone results showed revenue of $388.2M (+2.7% YoY), diluted EPS of $1.11 (flat YoY), and adjusted diluted EPS of $1.55 (−1.3% YoY).
Why this rating
Acquisition at ~1.9× 2026 annualized revenue fundamentally transforms company into subsidiary; deal magnitude (~$8B) approaches 186% of market cap ($4.3B), making it transformational. Standalone Q2 performance slightly below prior year masks pending exit; business-changing event regardless of near-term operational trends.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.